TFF Pharmaceuticals, Inc. Common Stock
TFFP
TFFP was delisted on the 12th of December, 2024.
43 hedge funds and large institutions have $26.8M invested in TFF Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 14 increasing their positions, 14 reducing their positions, and 9 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 14
16% less funds holding
Funds holding: 51 → 43 (-8)
16% less call options, than puts
Call options by funds: $950K | Put options by funds: $1.14M
35% less capital invested
Capital invested by funds: $41M → $26.8M (-$14.1M)
89% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 9
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Carlson Capital
Dallas,
Texas
|
+$594K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$341K |
| 3 |
WIM
Westside Investment Management
Santa Monica,
California
|
+$171K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$66.9K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$60.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.29M |
| 2 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$650K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$427K |
| 4 |
MA
MYDA Advisors
Woodmere,
New York
|
-$355K |
| 5 |
IA
IndexIQ Advisors
New York
|
-$276K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| – | -$8K | -37 | Closed |
|
|
GAM
52
Gemmer Asset Management
Walnut Creek,
California
| – | -$4K | -20 | Closed |
|
TFFP Hedge Fund Activity: Q1 2022 in Review
43 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in TFF Pharmaceuticals, Inc. Common Stock (TFFP) for Q1 2022, worth a combined $26.8M — down 35% from $41M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TFFP and 1 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 14 added.
The largest buyer was Carlson Capital, adding an estimated $594K. The largest seller was Susquehanna International Group, cutting an estimated $1.29M.
- 43 institutional investors held TFF Pharmaceuticals, Inc. Common Stock (TFFP) as of Q1 2022, down from 51 in Q4 2021.
- Funds reported $26.8M of TFF Pharmaceuticals, Inc. Common Stock stock for Q1 2022, down 35% quarter-over-quarter.
- 1 fund opened new TFF Pharmaceuticals, Inc. Common Stock positions in Q1 2022 and 9 closed out, a net change of -8 holders.
- The largest TFF Pharmaceuticals, Inc. Common Stock buyer in Q1 2022 was Carlson Capital, an estimated $594K added.
- The largest TFF Pharmaceuticals, Inc. Common Stock seller in Q1 2022 was Susquehanna International Group, an estimated $1.29M sold.
Based on aggregated 13F filings for Q1 2022.